Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Many ovarian cancers originate from ovarian surface epithelium, where they develop from cysts intermixed with stroma. The stromal layer is critical to the progression and survival of the neoplasm and consequently is recruited into the tumor microenvironment. Using both syngenic mouse tumors (ID8-R), and human xenograft (OVCAR3, SKOV3) tumor models, we first confirmed intraperitoneally-circulating MSC could target, preferentially engraft and differentiate into α-SMA+ myofibroblasts, suggesting their role as “reactive stroma” in ovarian carcinoma development and confirming their potential as a targeted delivery vehicle for the intratumoral production of interferon-beta (IFNβ). Then, mice with ovarian carcinomas received weekly IP injections of IFNβ expressing MSC, resulting in complete eradication of tumors in 70% of treated OVCAR3 mice (P = 0.004) and an increased survival of treated SKOV3 mice compared with controls (P = 0.01). Similar tumor growth control was observed using murine IFNβ delivered by murine MSC in ID8-R ovarian carcinoma. As a potential mechanism of tumor killing, MSC produced IFNβ induced caspase-dependent tumor cell apoptosis. Our results demonstrate that ovarian carcinoma engraft MSC to participate in myofibrovascular networks and that IFNβ produced by MSC intratumorally modulates tumor kinetics, resulting in prolonged survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · cited 1×
“IFN-b has been shown to boost the transcription of the p53 gene and increase its protein levels (41).”
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis
Chawla-Sarkar, M., Lindner, D. J., Liu, Y.-F., Williams, B. R., Sen, G. C., Silverman, R. H., & Borden, E. C. (2003) · Apoptosis · doi:10.1023/a:1023668705040 · Cited by 829
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Self-citationDevelopment of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593
Self-citationInflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells
Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008) · Gene Therapy · doi:10.1038/gt.2008.39 · Cited by 579
Self-citationKlopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 1×
“(36) published a thorough review of articles showing the promotion or inhibition of tumor growth by MSCs.”
Self-citationMulticellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0334 · Cited by 302 · cited 2×
“(14) demonstrated “preferential homing” of mesenchymal progenitor cells, a potentially similar stem cell, into xenotransplanted tumors in SCID mice, while observing no engraftment in normal organs.”
Research works printed but not linked: 35
- Kenny, 2008, The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin, J Clin Invest, 118, 1367, 10.1172/JCI33775 · DOI · Paper page
- Ghahremani, 1999, Etiology of ovarian cancer: a proposed mechanism, Med Hypotheses, 52, 23, 10.1054/mehy.1997.0620 · doi:10.1054/mehy.1997.0620
- Prockop, 1997, Marrow stromal cells as stem cells for nonhematopoietic tissues, Science, 276, 71, 10.1126/science.276.5309.71 · DOI · Paper page
- Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143 · DOI · Paper page
- Dvorak, 1986, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, N Engl J Med, 315, 1650, 10.1056/NEJM198612253152606 · DOI · Paper page
- Xu, 2010, Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro, Oncol Rep, 23, 1561, 10.3892/or_00000796 · DOI
- Coffelt, 2009, The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells, Proc Natl Acad Sci USA, 106, 3806, 10.1073/pnas.0900244106 · DOI · Paper page
- Studeny, 2002, Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors, Cancer Res, 62, 3603
- Studeny, 2004, Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents, J Natl Cancer Inst, 96, 1593, 10.1093/jnci/djh299 · DOI · Paper page
- Studeny, 2001, Bone marrow derived mesenchymal stem cells serve as precursors for stromal fibroblasts in malignant tumors and show potential for cancer therapy, Blood, 98
- Hu, 2011, Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice, Biotechnol Appl Biochem, 58, 397, 10.1002/bab.63 · DOI
- Hata, 2010, Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas, Neurosurgery, 66, 144, 10.1227/01.NEU.0000363149.58885.2E · DOI · Paper page
- Wong, 1989, Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines, Int J Cancer, 43, 526, 10.1002/ijc.2910430331 · DOI
- Johns, 1992, Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β, J Natl Cancer Inst, 84, 1185, 10.1093/jnci/84.15.1185 · DOI
- Chawla-Sarkar, 2001, Preferential induction of apoptosis by interferon (IFN)-β compared with IFN-α2: correlation with TRAIL/Apo2L induction in melanoma cell lines, ClinCancer Res, 7, 1821
- Zhang, 1999, Induction of multiple programmed cell death pathways by IFN-β in human non-small-cell lung cancer cell lines, ExpCell Res, 247, 133
- Rambaldi, 1985, Intraperitoneal administration of interferon β in ovarian cancer patients, Cancer, 56, 294, 10.1002/1097-0142(19850715)56:2<294::AID-CNCR2820560216>3.0.CO;2-K · doi:10.1002/1097-0142(19850715)56:2<294::aid-cncr2820560216>3.0.co;2-k
- Kardamakis, 1991, Interferons in the treatment of malignancies, In Vivo, 5, 589
- Cappelli, 1992, The locoregional treatment of neoplastic ascites with interferon-beta, Recenti Prog Med, 83, 82
- Einhorn, 1996, Why do so many cancer patients fail to respond to interferon therapy?, J Interferon Cytokine Res, 16, 275, 10.1089/jir.1996.16.275 · DOI
- Buchwalder, 2000, Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers, JInterferon Cytokine Res, 20, 857, 10.1089/10799900050163226 · DOI
- Salmon, 1996, Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers, J Interferon Cytokine Res, 16, 759, 10.1089/jir.1996.16.759 · DOI · Paper page
- Johns, 1990, Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and murine α interferons in mice, Cancer Res, 50, 4718
- Pan, 2005, Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response, J Cancer Res Clin Oncol, 131, 468, 10.1007/s00432-004-0651-y · doi:10.1007/s00432-004-0651-y
- Streck, 2005, Adeno-associated virus vector-mediated systemic delivery of IFN-β combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models, Clin Cancer Res, 11, 6020, 10.1158/1078-0432.CCR-05-0502 · DOI · Paper page
- Yotnda, 2004, Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses, Hum Gene Ther, 15, 1229, 10.1089/hum.2004.15.1229 · doi:10.1089/hum.2004.15.1229
- Odaka, 2001, Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity, Cancer Res, 61, 6201
- François, 2006, Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage, Stem Cells, 24, 1020, 10.1634/stemcells.2005-0260 · DOI · Paper page
- Saidi, 2006, Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines, Am J Surg, 191, 358, 10.1016/j.amjsurg.2005.10.037 · DOI
- Morrison, 2005, Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma, Biochem J, 385, 595, 10.1042/BJ20040971 · DOI
- Fulda, 2006, 5-Aza-2′-deoxycytidine and IFN-γ cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8, Oncogene, 25, 5125, 10.1038/sj.onc.1209518 · DOI
- Gómez-Benito, 2005, Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-α in human myeloma cells, FEBS Lett, 579, 6217, 10.1016/j.febslet.2005.10.007 · doi:10.1016/j.febslet.2005.10.007
- De Feudis, 1997, DDP-induced cytotoxicity is net influenced by p53 in nine human ovarian cancer cell lines with different p53 status, Br J Cancer, 76, 474, 10.1038/bjc.1997.412 · doi:10.1038/bjc.1997.412
- Matuskova, 2010, HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells, Cancer Lett, 290, 58, 10.1016/j.canlet.2009.08.028 · DOI · Paper page
- Sonabend, 2008, Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma, Stem Cells, 26, 831, 10.1634/stemcells.2007-0758 · DOI · Paper page
Cited by
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Cell or Cell Membrane-Based Drug Delivery Systems
Tan, S., Wu, T., Zhang, D., & Zhang, Z. (2015) · Theranostics · doi:10.7150/thno.11852 · Cited by 466
“For example, SCs with genetic modification could secret therapeutic agents in tumor tissue, such as tumor necrosis factor–related apoptosis–inducing ligand (TRAIL)[76, 77], interferon-β (IFN-β)[78, 79], IL12/18[80-82], to inhibit the growth of the tumor.”
BackgroundNanocarrier-based systems for targeted and site specific therapeutic delivery
Majumder, J., Taratula, O., & Minko, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.010 · Cited by 394
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37
“MSCs expressing IFN-β can reduce tumour size, induce apoptosis and increase survival in the aforementioned cancer types [55,102,103,104,105,106,107,108].”
BackgroundQiao, B., Shui, W., Cai, L., Guo, S., & Jiang, D. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s77116 · Cited by 30
Metadata
- Authors
- Dembinski, J. L., Wilson, S. M., Spaeth, E. L., Studeny, M., Zompetta, C., Samudio, I., Roby, K., Andreeff, M., & Marini, F. C.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 15
- Issue
- 1
- Pages
- 20-32.e2
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2052489552
- Cited by
- 77
- References
- 8
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Cancer Institute (CA-1094551, Ca-116199, RC1CA146381, P50CA083639, R01CA109451, R01NS06994, CA-55164, CA-16672, CA-49639)
- Susan G. Komen Breast Cancer Foundation (BC083397)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.